Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery

References

• JaanusSDLesherGAAnti-inflammatory drugsBartlettJDJaanusSDClinical Ocular Pharmacology3rd edBoston, MAButterworth-Heinemann1995
   Google Scholar
• BeckerBIntraocular pressure response to topical corticosteroidsInvest Ophthalmol19654219820514283013
   PubMedGoogle Scholar
• ArmalyMFEffects of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eyeArch Ophthalmol1963701048249114078870
   PubMedGoogle Scholar
• BurdeRMBeckerBCorticosteroid-induced glaucoma and cataracts in contact lens wearersJAMA197021312207520785468759
   PubMed Web of Science ®Google Scholar
• BodorNLoftssonTWuWMMetabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonatePharm Res1992910127512781448425
   PubMed Web of Science ®Google Scholar
• DruzgalaPWuWMBodorNOcular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyesCurr Eye Res199110109339371959381
   PubMed Web of Science ®Google Scholar
• BartlettJDHorwitzBLaibovitzRHowesJFIntraocular pressure response to loteprednol etabonate in known steroid respondersJ Ocul Pharmacol1993921571658345288
   PubMedGoogle Scholar
• NovackGDHowesJCrockettRSSherwoodMBChange in intraocular pressure during long-term use of loteprednol etabonateJ Glaucoma1998742662699713785
   PubMed Web of Science ®Google Scholar
• ManabeSBucalaRCeramiANonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataractsJ Clin Invest1984745180318106501572
   PubMed Web of Science ®Google Scholar
• Lotemax [Package insert]Rochester, NYBausch and Lomb Inc2006
   Google Scholar
• AsbellPHowesJA double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitisCLAO J199723131369001768
   PubMedGoogle Scholar
• FriedlanderMHHowesJAA double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group 1Am J Ophthalmol199712344554649124242
   PubMed Web of Science ®Google Scholar
• DellSJShulmanDGLowryGMHowesJA controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study GroupAm J Ophthalmol199712367917979535623
   PubMed Web of Science ®Google Scholar
• PflugfelderSCMaskinSLAndersonBNovackGDHartKA randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearanceAm J Ophthalmol2004138344445715364229
   PubMed Web of Science ®Google Scholar
• Loteprednol Etabonate US Uveitis Study GroupControlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitisAm J Ophthalmol1999127553754410334346
   PubMed Web of Science ®Google Scholar
• StewartRHorwitzBHowesJNovakGDHartKDouble-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Postoperative Inflammation Study Group 1J Cataract Refract Surg19982410148014899818338
   PubMed Web of Science ®Google Scholar
• Loteprednol Etabonate Postoperative Inflammation Study Group 2A double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammationOphthalmology19981059178017869754192
   PubMed Web of Science ®Google Scholar
• HollandEJBartlettJDPaternoMRUsnerDWComstockTLEffects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteersCornea2008271505518245967
   PubMed Web of Science ®Google Scholar
• WhiteEMMacyJIBatemanKMComstockTLComparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharo-keratoconjunctivitisCurr Med Res Opin200824128729618062846
   PubMed Web of Science ®Google Scholar
• AgrestiACategorical Data AnalysisNew York, NYJohn Wiley and Sons1990
   Google Scholar
• PavesioCEDeCoryHHTreatment of ocular inflammatory conditions with loteprednol etabonateBr J Ophthalmol200892445545918245274
   PubMed Web of Science ®Google Scholar
• FiscellaRGOphthalmic drug formulationsBartlettJDJaanusSDClinical Ocular Pharmacology5th edSt. Louis, MOButterworth-Heinemann2008
   Google Scholar
• Fluorometholone [Package insert]Irvine, CAAllergan Inc2001
   Google Scholar
• StewartRSControlled evaluation of fluorometholone acetate and loteprednol etabonate in the treatment of postoperative inflammation following cataract surgeryInvest Ophthalmol Vis Sci200445Suppl 1U159
   Google Scholar
• Flarex [Package insert]Fort Worth, TXAlcon Laboratories Inc1999
   Google Scholar
• TakahashiNCytotoxicity of mercurial preservative in cell cultureOphthalmic Res1982141163697070758
   PubMed Web of Science ®Google Scholar
• HerbstRAUterWPirkerCGeierJFroschPJAllergic and non-allergic periorbital dermatitis: Patch test results of the Information Network of the Departments of Dermatology during a 5-year periodContact Dermatitis2004511131915291826
   PubMed Web of Science ®Google Scholar
• HowesJFBaruHVeredMNeumannRLoteprednol etabonate: Comparison with other steroids in two models of intraocular inflammationJ Ocular Pharmacol1994101289293
   Google Scholar
• SamudreSSLattanzioFAWilliamsPBSheppardJDComparison of topical steroids for acute anterior uveitisJ Ocular Pharmacol Ther2004206533547
   PubMed Web of Science ®Google Scholar
• BilgihanKGurelikGAkataFHasanreisogluBFluorometholone-induced cataract after photorefractive keratectomyOphthalmologica199721163943969380362
   PubMed Web of Science ®Google Scholar
• CostagliolaCCati-GiovannelliBPriccirrilloADelfinoMCataracts associated with long-term topical steroidsBr J Dermatol198912034724732713268
   PubMed Web of Science ®Google Scholar
• CantrillHLPalmbergPFZinkHAWaltmanSRPodosSMBeckerBComparison of in vitro potency of corticosteroids with ability to raise intraocular pressureAm J Ophthalmol1975796101210171173539
   PubMed Web of Science ®Google Scholar